Ribi Immunochem (ribi) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ribi Immunochem (ribi)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert Stewart who wrote (15)	1/10/1997 10:46:00 AM
From: Bill Tomko	of 92

Thank you for the news flash. I had spoken to SKFB yesterday and got most of the same information. Note the reference in the NEJM editorial discussed to "---Striking effect of certain adjuvants----". Last fall (1996) SmithKline Beecham Biologicals prsented a very brief paper on the SKFB herpes vac. and I am quoting from the paper"The inclusion of MPL clearly contributed to a strong CML responce( lymphoproliferation and IFN-y and LI-2 secretion) invitro and in vivo (DTH skin test)". The papers conclusion was " The cuerrently developed herpes simplex vac. has been proven to be highly immunogenic and safe in > 1000 subjects and is currenly being evaluated for efficacy" My understanding is the phase III clinical will be concluded in 1997. As I said in my first posting, can anyone tell me why this stock is stuck at $4.00 and has almost $1.00 per share in cash to boot???? To say that I'm frustrated is a gross understatement. The QS-21 adjuvant used in the malaria test was from AQLA.Does anyone know anything about AQLA?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next